President Joe Biden tested positive for COVID-19 on Thursday morning, becoming infected at age 79 after more than two years of avoiding a known case while serving as president. The White House said he was experiencing mild symptoms, had begun taking the antiviral Paxlovid and would continue carrying out presidential duties while isolating in the residence. CBS News reported that an antigen test first detected the infection and a PCR test confirmed it.

White House physician Dr. Kevin O'Connor said Biden's initial symptoms included a runny nose, fatigue and an occasional dry cough. Biden is fully vaccinated and has received two booster doses, most recently in March. The administration's COVID-19 response coordinator, Dr. Ashish Jha, said those vaccinations and prompt antiviral treatment sharply reduce the president's risk of severe illness.

The diagnosis is politically and medically significant because Biden is the oldest person to serve as U.S. president and because his infection arrives during a summer wave driven largely by the highly transmissible BA.5 subvariant. An NPR report quoted Jha saying Biden's oxygen level was normal and that he was working from the residence rather than resting because of serious symptoms.

Vaccination and treatment change the risk profile

Biden's case illustrates how the clinical management of COVID-19 has changed since the first year of the pandemic. When President Donald Trump contracted the virus in October 2020, vaccines were not yet available and he was hospitalized at Walter Reed National Military Medical Center. Biden now has four vaccine doses and access to an oral antiviral authorized for people at high risk of progression to severe disease.

Paxlovid, a combination of nirmatrelvir and ritonavir, received emergency authorization in December 2021 and is intended for patients with mild-to-moderate COVID-19 who face elevated risk of hospitalization or death. The FDA had expanded access earlier this month by allowing state-licensed pharmacists to prescribe the drug under specified conditions. The agency's authorization record shows the treatment's December 22, 2021 emergency authorization and a July 6, 2022 update permitting pharmacist prescribing.

Because age is among the strongest risk factors for severe COVID-19, Biden's medical team moved quickly. Bloomberg's July 21 account reported that he began Paxlovid the day of his positive test and that O'Connor expected him to respond favorably given his vaccination status and treatment.

The White House is emphasizing continuity of government

The administration immediately sought to demonstrate that the infection was not interrupting presidential decision-making. Biden canceled travel to Pennsylvania but participated in scheduled meetings by phone and videoconference. Chief of Staff Ron Klain told White House employees that officials had long anticipated the possibility that the president would eventually contract the virus and had prepared a plan for him to continue working from the residence.

The White House also began notifying people considered close contacts. Vice President Kamala Harris and first lady Jill Biden both tested negative Thursday. The president had returned days earlier from a Middle East trip and had traveled to Massachusetts on Wednesday, creating a sizable contact-tracing task across staff, lawmakers and others who had been near him.

The Washington Post reported that the White House intended to provide daily medical updates and that officials were framing the case as evidence of the protection now available through vaccines, boosters and antiviral drugs. That messaging is important because the administration has been urging older Americans and other higher-risk groups to stay current on vaccination and seek treatment quickly after a positive test.

BA.5 is making reinfection and breakthrough cases more common

Biden's infection also reflects the changed epidemiology of the pandemic. Omicron descendants have demonstrated greater ability to infect people with prior vaccination or infection than earlier variants. BA.5 has become dominant in the United States, producing a new wave of cases even as vaccines continue to provide substantially stronger protection against hospitalization and death than against any infection.

An NPR/OPB report noted that Biden was vaccinated and twice boosted and that the White House described his symptoms as very mild. The diagnosis therefore does not indicate that vaccination failed in its most important purpose; rather, it highlights the narrower protection against infection created by newer variants and the continuing importance of layered protection for older adults.

By Friday, Biden's physician said the president had completed a full day of Paxlovid and was improving. An Associated Press report said Biden had recorded a temperature of 99.4 degrees Fahrenheit on Thursday that returned to normal after Tylenol, while his oxygen saturation, blood pressure and respiratory rate remained normal. He continued meetings and intelligence briefings, though his voice was noticeably hoarse.

A presidential case becomes a public-health test case

The White House is attempting to turn Biden's infection into a demonstration of how COVID-19 can be managed when high-risk patients have access to vaccination, testing and treatment. Officials have repeatedly stressed that the president's situation is different from the severe cases that dominated the pandemic before vaccines and antivirals became available.

That comparison is not a guarantee about the course of illness. Older age remains a meaningful risk factor, and Biden's medical team will continue monitoring him for worsening respiratory symptoms and for a possible return of symptoms after treatment. But the first two days of public updates indicate a mild illness managed at the White House rather than a medical emergency requiring hospitalization.

The broader challenge is that the tools protecting the president are not uniformly used across the country. Millions of Americans have not received booster doses, and many patients eligible for antiviral treatment do not receive it promptly. The president's case gives the administration an unusually visible opportunity to reinforce its central message: infection can still occur, but vaccination and early treatment can substantially change what follows.